Voxilaprevir
Cat. No.：YN252066
| 产品名称: | Voxilaprevir |
| CAS No.: | 1535212-07-7 |
| Chemical Name: | N-[[[(1R,2R)-2-[5,5-difluoro-5-(3-hydroxy-6-methoxy-2-quinoxalinyl)pentyl]cyclopropyl]oxy]carbonyl]-3-methyl-L-valyl-(3S,4R)-3-ethyl-4-hydroxy-L-prolyl-1-amino-2-(difluoromethyl)-N-[(1-methylcyclopropyl)sulfonyl]-cyclopropanecarboxamide, cyclic (1R→2R)-et |
| Synonyms: | 伏西瑞韦; GS-9857 |
| 分子量: | 868.9355328 |
| 分子式: | C40H52F4N6O9S |
| SMILES: | O=C([C@H]([C@H](CC)[C@]([H])(C1)OC2=NC3=CC(OC)=CC=C3N=C2C(F)(CCCC[C@@]4([H])[C@](C4)([H])OC(N[C@H]5C(C)(C)C)=O)F)N1C5=O)N[C@]6([C@@H](C6)C(F)F)C(NS(=O)(C7(CC7)C)=O)=O |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Voxilaprevir (GS-9857) 是一种非共价、可逆的HCVNS3/4A蛋白酶抑制剂 (PI)，具有泛抗病毒活性。Voxilaprevir 抑制基因型 1b 和 3a 野生型 NS3 蛋白酶的Ki值分别为 0.038 nM 和 0.066 nM。Voxilaprevir 是一种具有口服活性直接作用型抗病毒试剂 (DAA)，可用于HCV感染的研究。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Taylor, J.G., Zipfel, S., Ramey, K., et al.Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi®Bioorg. Med. Chem. Lett.29(16),2428-2436(2019)
